verapamil has been researched along with Wilms Tumor in 1 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Wilms Tumor: A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etoposide was given daily (150 mg m-2 day-1) for three doses (each over 1 h); the first dose was given 12 h into the verapamil infusion." | 2.68 | Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. ( Cowie, FJ; Dick, G; Flanagan, RJ; Judson, I; McCarthy, PT; Phillips, M; Pinkerton, CR, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cowie, FJ | 1 |
| Pinkerton, CR | 1 |
| Phillips, M | 1 |
| Dick, G | 1 |
| Judson, I | 1 |
| McCarthy, PT | 1 |
| Flanagan, RJ | 1 |
1 trial available for verapamil and Wilms Tumor
| Article | Year |
|---|---|
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resis | 1995 |